PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Ruxolitinib
Related studies linked through entity extraction aliases.
Ruxolitinib in Thrombocythemia and Polycythemia Vera
- Status
- RECRUITING
- Phase
- PHASE2
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Inflammatory Signal Inhibitors for COVID-19 (MATIS)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
- Status
- TERMINATED
- Phase
- PHASE3
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
- Status
- TERMINATED
- Phase
- PHASE3
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
- Status
- TERMINATED
- Phase
- PHASE2
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
- Status
- COMPLETED
- Phase
- PHASE3
Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica
- Status
- COMPLETED
- Phase
- PHASE2
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis
- Status
- TERMINATED
- Phase
- PHASE1
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE3
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia
- Status
- UNKNOWN
- Phase
- PHASE4
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
- Status
- TERMINATED
- Phase
- PHASE3